home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
The Pier Shareware 6
/
The_Pier_Shareware_Number_6_(The_Pier_Exchange)_(1995).iso
/
026
/
med9410a.zip
/
M94A0093.TXT
< prev
next >
Wrap
Text File
|
1994-10-01
|
2KB
|
38 lines
Document 0093
DOCN M94A0093
TI Lipid-based amphotericin B in the treatment of cryptococcosis.
DT 9412
AU Viviani MA; Rizzardini G; Tortorano AM; Fasan M; Capetti A; Roverselli
AM; Gringeri A; Suter F; Laboratorio di Micologia Medica, Universita
degli Studi di; Milano, Italy.
SO Infection. 1994 Mar-Apr;22(2):137-42. Unique Identifier : AIDSLINE
MED/94350503
AB Amphotericin B is the only antifungal drug which, despite its
dose-limiting toxicity, can be given intravenously when an aggressive
treatment is required. In an attempt to reduce the drug toxicity while
retaining its therapeutic efficacy, new formulations of amphotericin B
have been developed. The most promising have employed lipid vehicles
such as liposomes. Three lipid-based amphotericin B formulations have
been developed by pharmaceutical companies and are under active clinical
investigation. Efficacy and safety data of these derivatives in animals
and humans are reviewed, with particular concern to cryptococcal
infection. The authors' experience with a small unilamellar liposomal
amphotericin B formulation, AmBisome, in the primary therapy of
cryptococcosis is reported. Nine AIDS patients affected with
cryptococcosis, seven of whom had meningitis, were given AmBisome (3
mg/kg/day) for 3-6 weeks. Complete response was obtained in six
patients, marked improvement in two, and failure in one. AmBisome was
well tolerated and shortened the time to clinical and mycological
response suggesting a further improvement in the management of
cryptococcosis in AIDS patients.
DE Adult Amphotericin B/*ADMINISTRATION & DOSAGE/PHARMACOLOGY/THERAPEUTIC
USE AIDS-Related Opportunistic Infections/BLOOD/DIAGNOSIS/*DRUG
THERAPY Chemistry, Pharmaceutical Cryptococcosis/BLOOD/DIAGNOSIS/*DRUG
THERAPY Drug Carriers Drug Evaluation Human Leukocyte Count
Liposomes Male Middle Age Pilot Projects Time Factors Treatment
Outcome T4 Lymphocytes JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).